IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.82+0.00 (+0.49%)
Close on Nov 17, 2026Market cap $8.08MP/E –Yield –
IN8bio r&d expenses
Research and development expenses are spending on new products and technology.
IN8bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.86M, down 20.3% year over year. For fiscal 2025 it was $10.21M, down 39.8% from the year before. The highest annual figure on record is $16.96M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.21M | -39.8% |
| FY2024 | Dec 31, 2024 | $16.96M | +0.8% |
| FY2023 | Dec 31, 2023 | $16.83M | +19.7% |
| FY2022 | Dec 31, 2022 | $14.06M | +91.4% |
| FY2021 | Dec 31, 2021 | $7.35M | +36.6% |
| FY2020 | Dec 31, 2020 | $5.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.49M | +0.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.61M | -12.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.65M | -26.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.10M | -36.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.49M | -51.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.97M | -39.4% |
| Q4 FY2024 | Dec 31, 2024 | $3.59M | -20.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.31M | -12.6% |
| Q2 FY2024 | Jun 30, 2024 | $5.16M | +24.7% |
| Q1 FY2024 | Mar 31, 2024 | $4.90M | +11.8% |
| Q4 FY2023 | Dec 31, 2023 | $4.52M | +15.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.79M | -11.0% |
| Q2 FY2023 | Jun 30, 2023 | $4.13M | +18.0% |
| Q1 FY2023 | Mar 31, 2023 | $4.39M | +84.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.92M | +46.0% |
| Q3 FY2022 | Sep 30, 2022 | $4.26M | +215.2% |
| Q2 FY2022 | Jun 30, 2022 | $3.50M | +69.8% |
| Q1 FY2022 | Mar 31, 2022 | $2.38M | +91.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.69M | +80.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.35M | +27.7% |
| Q2 FY2021 | Jun 30, 2021 | $2.06M | +15.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.25M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.49M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.06M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.78M | – |
See a number that looks wrong?